Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Pediatr Nephrol. 2013 Feb 17;28(6):939–949. doi: 10.1007/s00467-013-2419-6

Table 2.

Cardiovascular Disease Care (CVD)

Variable Patient level: care documented/care recommended (%)
Center Level
All Patients Formal Transition No Formal Transition Odds Ratio (or regression coefficienta) p-value Mean % documented care across centers Range % documented care across centers p-valueb
CVD risk assessment
 Smoking history 145/196 (74%) 48/59 (81%) 97/137 (71%) 24.10 <0.01 80% 38% – 100% 0.14
 Echocardiogram (if hypertensive) 105/149 (70%) 37/48 (77%) 68/101 (67%) 1.30 0.67 77% 10% – 100% 0.13
 Family history of CVDc 103/196 (53%) 26/59 (44%) 77/137 (56%) 1.24 0.81 51% 0% – 80% 0.16
 Fasting lipid profile 93/196 (47%) 35/59 (59%) 58/137 (42%) 2.97 0.06 46% 19% – 75% 0.17
 Physical activity assessment 92/196 (47%) 25/59 (42%) 67/137 (49%) 4.62 0.04 51% 14% – 100% 0.12

Composite CVD Risk Assessment 538/933 (58%) 171/284 (60%) 367/649 (57%) 0.21a <0.001 57% 44% – 86% 0.08

Therapy for modifiable CVD risk factors
 Blood pressure medication (if hypertensive) 107/132 (81%) 36/44 (82%) 71/88 (81%) 0.65 0.58 84% 29% – 100% 0.19
 Dietary counseling by dietician 117/165 (71%) 46/56 (82%) 71/109 (65%) 45.00 0.21 72% 15% – 100% 0.17
 Lipid lowering agent (if elevated total cholesterol or LDL) 16/36 (44%) 9/12 (75%) 7/24 (29%) 8.40 0.18 46% 0% – 100% N/Ad
 Endocrine referral (if hyperglycemic) 11/50 (22%) 5/26 (19%) 6/24 (25%) 0.71 0.62 22% 0% –100% N/Ad
 Smoking cessation counseling (if smoker) 5/28 (18%) 0/7 (0%) 5/21 (24%) N/A N/A 89% 0% –100% 0.52
 Exercise therapy or referral (if BMI > 30) 4/42 (10%) 0/15 (0%) 4/28 (14%) N/A N/A 95% 0% –25% N/Ad

Composite CVD Therapy 260/454 (57%) 96/160 (60%) 164/294 (56%) 0.09a 0.19 56% 27% – 76% 0.09
a

Regression estimate reflecting the percentage increase in indicated care that was documented

b

Based on variance estimate

c

Cardiovascular Disease

d

Insufficient numbers to compute